The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can
aid in objectively diagnosing patients and providing individualized treatment …

Impairment of insulin action and metabolic dysregulation have traditionally been associated
with schizophrenia, although the molecular basis of such association remains still elusive …

Psychiatric disorders impose tremendous economic burden on society and are leading
causes of disability worldwide. However, only limited drugs are available for psychiatric …

Comprehending the pathogenesis of schizophrenia represents a challenge for global
mental health. To date, although it is evident that alterations in dopaminergic, serotonergic …

Abstract Background and Objectives Although therapeutic drug monitoring of clozapine is
recommended, its optimisation is often adjusted only on the basis of dosage. The aim of this …

This study aimed to identify the 20‐year trajectories of positive and negative symptoms after
the first psychotic episode in a sample of patients with an ICD‐10 diagnosis of schizophrenia …

Introduction Treatment of severe mental illness (SMI) symptoms, especially negative
symptoms and cognitive dysfunction in schizophrenia, remains a major unmet need. There …

Extracellular vesicles (EVs) have emerged as an attractive liquid biopsy approach in the
diagnosis and prognosis of multiple diseases and disorders. The feasibility of enriching …

Schizophrenia has been conceptualized as a neurodevelopmental disorder with synaptic
alterations and aberrant cortical–subcortical connections. Antipsychotics are the mainstay of …

Treatment-resistant schizophrenia (TRS) often results in severe disability and functional
impairment. Currently, the diagnosis of TRS is largely exclusionary and emphasizes the …